ProKidney (PROK) Competitors $2.72 -0.02 (-0.73%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$2.74 +0.02 (+0.70%) As of 09/24/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PROK vs. CNTA, APLS, CGON, MOR, XENE, RARE, NAMS, OGN, IMVT, and KNSAShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Centessa Pharmaceuticals (CNTA), Apellis Pharmaceuticals (APLS), CG Oncology (CGON), MorphoSys (MOR), Xenon Pharmaceuticals (XENE), Ultragenyx Pharmaceutical (RARE), NewAmsterdam Pharma (NAMS), Organon & Co. (OGN), Immunovant (IMVT), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. ProKidney vs. Its Competitors Centessa Pharmaceuticals Apellis Pharmaceuticals CG Oncology MorphoSys Xenon Pharmaceuticals Ultragenyx Pharmaceutical NewAmsterdam Pharma Organon & Co. Immunovant Kiniksa Pharmaceuticals International Centessa Pharmaceuticals (NASDAQ:CNTA) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Which has preferable earnings and valuation, CNTA or PROK? ProKidney has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M468.59-$235.76M-$1.79-13.39ProKidney$80K10,005.52-$61.19M-$0.57-4.77 Does the media favor CNTA or PROK? In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than ProKidney. MarketBeat recorded 6 mentions for Centessa Pharmaceuticals and 4 mentions for ProKidney. ProKidney's average media sentiment score of 0.88 beat Centessa Pharmaceuticals' score of 0.81 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of CNTA or PROK? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 41.5% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is CNTA or PROK more profitable? ProKidney's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.39% -29.87% ProKidney N/A N/A -17.11% Do analysts prefer CNTA or PROK? Centessa Pharmaceuticals presently has a consensus price target of $32.38, suggesting a potential upside of 35.06%. ProKidney has a consensus price target of $6.25, suggesting a potential upside of 129.78%. Given ProKidney's higher probable upside, analysts plainly believe ProKidney is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10ProKidney 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk and volatility, CNTA or PROK? Centessa Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. SummaryProKidney beats Centessa Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$806.33M$2.56B$5.77B$10.42BDividend YieldN/A56.32%5.68%4.61%P/E Ratio-4.7723.6376.2826.42Price / Sales10,005.52750.89552.28127.65Price / CashN/A174.1537.5661.52Price / Book-0.805.2913.186.39Net Income-$61.19M$32.95M$3.29B$271.13M7 Day Performance0.37%1.40%0.84%0.93%1 Month Performance15.74%6.35%5.03%7.52%1 Year Performance32.04%2.70%71.27%30.06% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney3.6131 of 5 stars$2.72-0.7%$6.25+129.8%+19.3%$806.33M$80K-4.773CNTACentessa Pharmaceuticals3.2337 of 5 stars$21.85+2.4%$32.44+48.5%+54.4%$2.93B$15M-12.21200Insider TradeAPLSApellis Pharmaceuticals4.1096 of 5 stars$23.13-2.9%$34.12+47.5%-26.0%$2.92B$781.37M-12.71770CGONCG Oncology2.5585 of 5 stars$37.72+5.5%$56.00+48.5%+0.4%$2.88B$1.14M-21.3161Insider TradeHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730XENEXenon Pharmaceuticals2.5701 of 5 stars$36.70+2.9%$53.30+45.2%-6.0%$2.83B$9.43M-10.34210Positive NewsRAREUltragenyx Pharmaceutical4.2965 of 5 stars$28.71-2.6%$81.50+183.9%-50.0%$2.77B$560.23M-5.191,294NAMSNewAmsterdam Pharma3.0905 of 5 stars$24.49-0.1%$41.55+69.6%+72.1%$2.76B$45.56M-15.124Positive NewsOGNOrganon & Co.4.5618 of 5 stars$10.45+0.9%$17.33+65.9%-47.1%$2.72B$6.40B3.884,000Positive NewsIMVTImmunovant2.0668 of 5 stars$15.11-1.2%$33.60+122.4%-46.3%$2.63BN/A-5.30120KNSAKiniksa Pharmaceuticals International2.7294 of 5 stars$35.43-1.0%$41.17+16.2%+47.6%$2.63B$423.24M885.97220Positive News Related Companies and Tools Related Companies CNTA Alternatives APLS Alternatives CGON Alternatives MOR Alternatives XENE Alternatives RARE Alternatives NAMS Alternatives OGN Alternatives IMVT Alternatives KNSA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PROK) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PROK Stock Alerts